Gene · 2030
SLC29A1: solute carrier family 29 member 1 (Augustine blood group)
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SLC29A1: solute carrier family 29 member 1 (Augustine blood group). Genes, record 2030. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2030
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99808 | Equilibrative nucleoside transporter 1 | 456 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents96
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12534732 B2 | 2026-01-27 | 922 | Q99808 | Espacenet |
| JP 2026012378 A | 2026-01-23 | 922 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64395 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64396 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64397 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64398 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64399 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64400 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64401 | Q99808 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64402 | Q99808 | Espacenet |
1 to 10 of 96
See all 96 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| DIPYRIDAMOLE | CHEMBL932 | Equilibrative nucleoside transporter 1 inhibitor | INHIBITOR |
Source ChEMBL
Trials20
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07199504 | DIPYRIDAMOLE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT05166876 | DIPYRIDAMOLE | PHASE2 | 2023-02-06 | ClinicalTrials.gov |
| NCT04424901 | DIPYRIDAMOLE | PHASE2 | 2023-04-21 | ClinicalTrials.gov |
| NCT04410328 | DIPYRIDAMOLE | PHASE3 | 2025-02-21 | ClinicalTrials.gov |
| NCT03015974 | DIPYRIDAMOLE | ClinicalTrials.gov | ||
| NCT02966119 | DIPYRIDAMOLE | PHASE3 | ClinicalTrials.gov | |
| NCT02782260 | DIPYRIDAMOLE | PHASE2 | ClinicalTrials.gov | |
| NCT02121756 | DIPYRIDAMOLE | PHASE1/PHASE2 | 2019-04-11 | ClinicalTrials.gov |
| NCT01612377 | DIPYRIDAMOLE | PHASE2 | ClinicalTrials.gov | |
| NCT01369745 | DIPYRIDAMOLE | PHASE2 | 2014-04-30 | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsNIH grants1,270
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SLC29A1 papers | Newest fiscal year |
|---|---|---|---|
| P30ES006694 | Southwest Environmental Health Sciences Center | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| T32ES007091 | Training in Environmental Toxicology of Human Disease | 8 | 2025 |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| R01CA132946 | Genomics of AML Prognosis | 7 | 2025 |
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 7 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 4 | 2025 |
| U10CA180886 | COG NCTN Network Group Operations Center - Year 11 STAR Act MCI and PEC Supplement | 4 | 2025 |
1 to 10 of 1,270Source NIH's project files
See all 1,270 nih grantsPapers2,306
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tissue compartment limits the apparent late-stage decline in hepatic ENT1. | Metabolism | 2026 | 42790774 | PubTator, text mining | PubMed |
| Nucleolin shields PTBP1 from autophagic degradation to sustain gemcitabine resistance in bladder cancer. | Drug Resist Updat | 2026 | 42790162 | PubTator, text mining | PubMed |
| Response to "Tissue compartment limits the apparent late-stage decline in hepatic ENT1". | Metabolism | 2026 | 42753861 | PubTator, text mining | PubMed |
| Enhancing gemcitabine uptake by promoting dimerization of ENT1 transporter improves response rates of patients with sarcoma. | J Clin Invest | 2026 | 42691249 | PubTator, text mining | PubMed |
| The Potential of Cannabidiol for the Treatment of Psychosis: Endocannabinoid Regulation of Serotonergic Neurotransmission via Serotonin 5-HT1A/2A Receptors. | Neurochem Res | 2026 | 42658346 | PubTator, text mining | PubMed |
| Anticonvulsant effects, safety, and sex-dependent molecular signatures of cannabidiol treatment in a preclinical model of audiogenic epilepsy. | Front Pharmacol | 2026 | 42630256 | PubTator, text mining | PubMed |
| Construction and validation of a nomogram for the diagnosis of postmenopausal osteoporosis. | Mol Med Rep | 2026 | 42596822 | PubTator, text mining | PubMed |
| ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma. | Drug Resist Updat | 2026 | 42585696 | PubTator, text mining | PubMed |
| Pan-cancer multi-omics analysis of pharmacogenomic alterations. | Front Bioinform | 2026 | 42558488 | PubTator, text mining | PubMed |
| Repurposed cAMP-Modulating Agents Enhance 5-Fluorouracil Response Through Membrane-Dependent Mechanisms. | Membranes (Basel) | 2026 | 42506183 | PubTator, text mining | PubMed |
1 to 10 of 2,306
See all 2,306 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2030
GET https://conductscience.org/api/genes/v1/2030/patents?page=2